On May 9, CASL will join ActionHepCanada, CanHepC Network, Canadian HBV Network, and Canadian Liver Foundation for #CanHepDay24 in Ottawa.

Join CASL's executives and members to amplify our call for the federal and provincial governments.  #HepCantWait

🔗bit.ly/3WBO3on

Unlock the toolbox for cirrhosis symptom management! From fatigue to pruritus, discover expert-led resources for clinicians including symptom assessment/management, drug dosing, & end of life considerations at cirrhosiscare.ca.

#LiverTwitter

Cancer drugs are increasingly approved with no evidence of improved overall survival or quality of life. The shift towards alternative endpoints and small effect sizes needs to be carefully balanced against the harms of therapy to patients.

Bishal Gyawali

thelancet.com/journals/lanon…

Such an honor to win the CGIT Shark Tank!!

Thanks American Gastroenterological Association (AGA) American Gastroenterological Association (AGA) Tech Summit for this opportunity to present the idea behind Arithmedics, the brain child of Vetri Venthan Elango.

Congrats to all the Shark Tank finalists and organizers!

~99% of patients diagnosed with NAFLD in the Target RWE ✨💊🔬 pragmatic real-world cohort meet MASLD criteria. Inferences made from NAFLD research are applicable to patients with MASLD.

So pleased to see the current manuscript being published in HEPATOLOGY Journal through the @AASLD Practice Metrics Committee pubmed.ncbi.nlm.nih.gov/38536021/

A short thread..

Important consensus multidisciplinary paper by AASLD regarding management of cirrhosis associated coagulopathy. No need for INR testing or prophylactic plasma for paracentesis/diagnostic endoscopy. Great work from Elliot Tapper Juliet Emamaullee MD PhD et al. journals.lww.com/hep/abstract/9…

Large meta-analysis reveals sequential NITs like FIB-4 or NFS, followed by LSM-VCTE, match the diagnostic performance of LSM-VCTE alone for #MASH screening. This cost-effective strategy reduces screen failures and biopsies in clinical trials, making a significant advance in

Recent article from JAMA Internal Medicine regarding how to manage the cost of medications; US focused article but provides valuable lessons for all providers regardless of jurisdiction Sahil Sandhu Ryan Nipp, MD, MPH Nikki Patel jamanetwork.com/journals/jamai…

OK, trolls won't listen, but this 👇 is NOT a gotcha... Haters post this, like, 20+ times a day.

It is a grant to research health misinformation from (the independent) CIHR & the result of an open & independent (v competitive) peer review process.

I didn't get a dime.

How much money does #Medicare waste each year on guideline-discordant bone therapy for prostate cancer?

Our answer, reported this week in JCO Oncology Practice:
$43 million per year

Even in the health care world, that ain't pocket change.
ascopubs.org/doi/10.1200/OP…
🧵
1/

Article from The BMJ regarding the role of cola in food bolus. In this RCT, no difference between outcomes between cola and non cola arms. bmj.com/content/383/bm…

Sometimes when you meet a patient with rare disease, you google it.

You hope to find a comprehensive resource

One that answers your (and the patient's) questions

This is that paper for common variable immunodeficiency (CVID) liver disease
journals.lww.com/hepcomm/fullte… #livertwitter

Do you know a #CASLmember who has displayed exemplary work within the Canadian hepatology landscape?

Nominate them to receive a 2024 CASL Education Excellence Award or CASL Research Excellence Award
(deadline Dec.15).

🔗hepatology.ca/current-award-…

journals.lww.com/hep/fulltext/2… Statement from AASLD EASLnews APASL News and Latin American Association for the study of the liver on terminology in alcohol associated/related liver disease which I support. Patient first language is critical to help eliminate stigma

Boosting this important article to #LiverTwitter #GITwitter with a link for free access to the article

Updates on interventional treatment of portal HTN by Juan G Abraldes
🔺First review pic 👇🏼
🔺start TIPS at 8 mmHg with goal below 12 (between PV and IVC)
🔺if pressure not below 12 with dilation to 10 mm, add NSBB
🔺see table 👇🏼for contraindications
#TLM23 #livertwitter

Updates of portal HTN guidance statement by Guadalupe GarciaTsao
🔺CSPH can be defined by
📍Collaterals on imaging
📍EV on endoscopy
📍LS>25, LS 20-25/Plt<150
🔺Carvedilol is the NSBB of choice 6.25-12.5 daily
🔺Goal is prevention of decompensation in the new

No. No. No!

Absolutely NO evidence to support & possible harm (iatrogenic injury, overdiagnosis, diagnostic cascade, cost to healthcare system, etc).

Exploiting fear for profit. Ugh.

Patients are lining up for $2,500 full-body MRI cnb.cx/3QzPfDL via Ashley Capoot cc

Recent paper on cost effectiveness of terlipressin for HRS in the US setting. Cost saving in this model versus MOA or norepinephrine!! Editorial note that cost saving is very unusual with new technology #LiverTwitter link.springer.com/article/10.100…